For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
12
views
16
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      901
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found

      Management of COVID-19 Coagulopathy in a Patient with Severe Haemophilia A

      case-report

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 54-year-old man with a long history of severe haemophilia A treated prophylactically with efmoroctocog alpha (3,000 IU twice weekly) was diagnosed with COVID-19 infection. He had multiple risk factors for COVID-19 severity including obesity, diabetes mellitus and hypertension. He required prolonged intensive care unit (ICU) stay due to the severity of respiratory failure until his death on day 24. During his ICU stay, he received a continuous infusion of efmoroctocog alpha in order to maintain factor VIII activity between 80 and 100%, together with therapeutic doses of low-molecular-weight heparin targeting anti-Xa activity above 0.5 IU/mol. He tolerated numerous invasive procedures without bleeding. At post-mortem examination, there was no evidence for thrombosis or haemorrhage in the different organs.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: found

          Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

          Ning Tang, Dengju Li, Xiong Wang … (2020)
          Abstract Background In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern. Objectives To describe the coagulation feature of patients with NCP. Methods Conventional coagulation results and outcomes of 183 consecutive patients with confirmed NCP in Tongji hospital were retrospectively analyzed. Results The overall mortality was 11.5%, the non‐survivors revealed significantly higher D‐dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission (P < .05); 71.4% of non‐survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during their hospital stay. Conclusions The present study shows that abnormal coagulation results, especially markedly elevated D‐dimer and FDP are common in deaths with NCP.
          Article 0 comments Cited 2922 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

            Maximilian Ackermann, Stijn Verleden, Mark Kuehnel … (2020)
            Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little is known about the associated morphologic and molecular changes in the peripheral lung of patients who die from Covid-19.
            Article 0 comments Cited 2845 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Incidence of thrombotic complications in critically ill ICU patients with COVID-19

              F.A. Klok, M.J.H.A. Kruip, N.J.M. van der Meer … (2020)
              Introduction COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Reports on the incidence of thrombotic complications are however not available. Methods We evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. Results We studied 184 ICU patients with proven COVID-19 pneumonia of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications. Conclusion The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. Our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence.
              Article 0 comments Cited 2488 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): AHA
                Journal ID (nlm-ta): Acta Haematol
                Journal ID (doi): 10.1159/issn.0001-5792
                Title: Acta Haematologica
                Publisher: S. Karger AG
                ISSN (Print): 0001-5792
                ISSN (Electronic): 1421-9662
                Publication date (Electronic): 25 September 2020
                Volume:
                Issue:
                Pages: 1-3
                Affiliations
                [_a] aDepartment of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium
                [_b] bDepartment of Haematology, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium
                Author notes
                *Philippe Hantson, Department of Intensive Care, Cliniques St-Luc, Avenue Hippocrate, 10, BE–1200 Brussels (Belgium), philippe.hantson@uclouvain.be
                Author information
                https://orcid.org/0000-0003-4409-3352
                Article
                Publisher ID: 510591 Other ID: Acta Haematol
                DOI: 10.1159/000510591
                PubMed ID: 32980842
                SO-VID: d8c9bc72-8d19-4faa-b49f-a75cda414969
                Copyright © © 2020 S. Karger AG, Basel
                License:

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Date received : 23 June 2020
                Date accepted : 31 July 2020
                Page count
                Pages: 3
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Internal medicine,Respiratory medicine,Clinical Psychology & Psychiatry,Microbiology & Virology,Infectious disease & Microbiology
                Keywords: Coagulopathy,COVID-19,Haemophilia
                Data availability:
                ScienceOpen disciplines: Internal medicine, Respiratory medicine, Clinical Psychology & Psychiatry, Microbiology & Virology, Infectious disease & Microbiology
                Keywords: Coagulopathy, COVID-19, Haemophilia

                Comments

                Comment on this article

                scite_

                Similar content901

                See all similar

                Cited by2

                See all cited by

                Most referenced authors518

                See all reference authors